Why Asthma Research Matters in the UK Right Now
Asthma affects around 5.4 million people in the UK, yet treatment responses vary considerably from one person to another. The UK Severe Asthma Registry tracks outcomes across specialist centres in Manchester, Belfast, Liverpool, Birmingham, Southampton, and London, painting a detailed picture of how patients respond to different therapies. What researchers have noticed is that around 5% of people with asthma live with a severe form of the condition — frequent attacks, impaired lung function, and ongoing symptoms despite regular inhaled steroids. For these individuals, standard treatments often fall short.
Clinical trials are not just about testing unproven drugs. Many UK-based studies now examine how existing medications can be used differently. The ABRA trial, run at Oxford University Hospitals and Guy's and St Thomas' NHS Foundation Trust, looked at whether a biologic injection called benralizumab could replace steroid tablets during acute asthma flare-ups. The results were striking: patients who received the injection experienced fewer treatment failures over 90 days compared to those on standard prednisolone. Trials like this reshape how clinicians think about everyday asthma management.
Another significant development involves depemokimab, an ultra-long-acting biologic approved in the UK in late 2025. Dosed just twice a year, it targets type 2 inflammation — a driver behind many cases of severe asthma. The SWIFT and ANCHOR phase III trials underpinning its approval demonstrated sustained reductions in exacerbations and fewer hospitalisations. For patients who previously juggled daily inhalers and frequent steroid courses, a twice-yearly injection represents a genuine shift in treatment philosophy.
Types of Asthma Trials Currently Recruiting
The landscape of asthma research in the UK spans several categories, and knowing what each involves helps prospective volunteers make informed decisions.
Biologic therapy trials tend to focus on severe eosinophilic or type 2 inflammation-driven asthma. These studies evaluate monoclonal antibodies — benralizumab, mepolizumab, dupilumab, and the newer depemokimab — often comparing them against placebo or existing treatments. Recruitment typically happens through specialist severe asthma centres attached to large NHS trusts.
Inhaler and combination therapy trials examine new devices or drug combinations. The recent launch of Enerzair Breezhaler, a triple-combination inhaler combining a LABA, ICS, and LAMA in a single capsule, followed the IRIDIUM phase III study. Trials of this nature often recruit patients whose asthma remains uncontrolled on current therapy and who have experienced at least one exacerbation in the previous year.
Digital intervention studies are gaining traction too. A randomised controlled trial coordinated through primary care practices in multiple UK locations is evaluating whether a digital social intervention — essentially a structured online support programme — can improve asthma control scores compared to usual care. These trials suit patients who cannot commit to frequent hospital visits but still want to contribute to research.
Observational studies, such as the REMISSION UK chart review across four specialist centres, analyse existing patient data to understand how biologics contribute to clinical remission. Participation in these is less demanding — they rarely require extra clinic visits, as researchers work with anonymised medical records.
The table below summarises the main categories and what they typically involve:
| Trial Category | Example Study | Typical Duration | Ideal For | Key Commitment |
|---|
| Biologic therapy | SWIFT/ANCHOR (depemokimab) | 12–52 weeks | Severe eosinophilic asthma | Regular injection visits |
| Inhaler/combination | IRIDIUM (triple therapy) | 26–52 weeks | Uncontrolled on ICS/LABA | Daily inhaler use + clinic visits |
| Digital intervention | Primary care social support RCT | 12 months | Mild-to-moderate asthma | Online engagement + 3-monthly check-ins |
| Observational | REMISSION UK | Retrospective | Severe asthma on biologics | Consent for data access only |
| Acute exacerbation | ABRA (benralizumab vs steroids) | 90-day follow-up | Eosinophilic flare-ups | Emergency department recruitment |
Who Can Join and What to Expect
Eligibility criteria vary considerably between studies, which is why many people who assume they are unsuitable turn out to be ideal candidates. Most trials require a confirmed asthma diagnosis, and age ranges often span 18 to 70 or older depending on the research question. Some studies specifically seek patients with frequent exacerbations — two or more per year is a common threshold. Others recruit people with stable, well-controlled asthma to serve as comparison groups.
A screening appointment usually comes first. Researchers run through medical history, perform lung function tests, and sometimes check blood eosinophil levels to determine which arm of a study a volunteer fits into. The process is thorough, and participants can withdraw at any point — this is enshrined in NHS research ethics protocols.
Tom, a 52-year-old engineer from Glasgow, joined a biologic trial after years of oral steroid dependence. "I was nervous about the commitment," he recalls, "but the team explained everything in plain English. I had more monitoring than I'd ever had through routine care — lung function every few weeks, blood work, and a direct phone line to the research nurse." His exacerbations dropped noticeably during the study period, and while he does not know whether he received the active drug or placebo, the structured monitoring alone gave him a clearer picture of his asthma patterns.
Practical considerations matter too. Most UK trials reimburse travel expenses for clinic visits. Some studies, particularly those involving digital interventions or occasional questionnaires, require minimal in-person attendance. The Be Part of Research website, run by the National Institute for Health and Care Research, allows users to search for asthma studies by postcode, filtering by travel distance and time commitment. Asthma + Lung UK also maintains updated listings of respiratory research actively recruiting across England, Scotland, Wales, and Northern Ireland.
Navigating the Decision: Practical Steps
Understanding what questions to ask before enrolling makes the process less daunting. Research teams expect prospective volunteers to have queries — it signals engagement, not reluctance.
First, ask about the phase of the trial. Phase II studies explore dosing and preliminary efficacy. Phase III trials, which are more common in asthma research, compare an intervention against standard treatment or placebo in larger groups. Phase IV studies examine long-term effects in real-world settings after a treatment is already approved. Each carries a different risk profile, and the research team should explain this clearly.
Second, clarify the time commitment and location. Some trials run for a full year with monthly visits; others involve a single appointment and remote follow-up. Knowing the difference helps volunteers plan around work and family responsibilities. Major asthma research hubs include Guy's Hospital and the Royal Brompton in London, Manchester University NHS Foundation Trust, Queen's University Belfast, and the University Hospitals of Leicester, but smaller centres and GP practices increasingly participate in primary care-led studies.
Third, understand the randomisation and blinding process. Many trials randomly assign participants to treatment or placebo groups, and neither the patient nor the clinician knows which one they are in. This might sound unsettling, but it is the foundation of reliable evidence. Participants in the placebo arm still receive standard care alongside the dummy treatment — nobody is left untreated.
Fourth, ask about post-trial access. In some studies, participants who respond well to an investigational drug can continue receiving it through an extension phase or a named patient programme after the main trial concludes. This is not guaranteed, but it is worth discussing at the screening stage.
The ISRCTN registry and ClinicalTrials.gov list UK asthma trials with detailed eligibility criteria and contact information. Many studies list a principal investigator's email address or phone number directly, making self-referral straightforward. For those who prefer a mediated route, GPs and practice nurses can often point patients toward suitable studies, particularly when asthma remains poorly controlled despite optimised treatment.
What Makes UK Asthma Research Distinctive
The UK's research infrastructure has several features that shape the experience for volunteers. The UK Severe Asthma Registry, which pools data from specialist centres nationwide, means that real-world evidence feeds back into trial design. Researchers can identify which patient subgroups are underrepresented in existing studies — younger adults, certain ethnic minorities, and those with coexisting conditions — and tailor recruitment accordingly.
Recent analysis from the registry highlighted that many severe asthma patients treated with biologics in routine NHS practice would not have met the strict eligibility criteria for the original phase III trials of those same drugs. This gap between trial populations and real-world patients is exactly why ongoing UK research, including observational studies and pragmatic trials embedded in clinic workflows, carries such weight.
Industry investment in UK respiratory research remains substantial. GSK, AstraZeneca, and other pharmaceutical companies run multiple trials through NHS sites, often in collaboration with university research groups. The depemokimab programme at Guy's Hospital, for instance, combines academic clinical expertise with industry funding, and patients benefit from the rigorous oversight that such partnerships require.
Charities also play a role beyond listing trials. Asthma + Lung UK funds investigator-led research and campaigns for greater public awareness of clinical research opportunities. Their materials emphasise that healthy volunteers are sometimes needed alongside those with active asthma — comparison data is essential for meaningful results.
For anyone considering their first step, the message from researchers and past participants alike is consistent: clinical trials in the UK operate within a framework of strict ethical oversight, and the decision to take part is entirely personal and reversible. The practical information is available; what takes longer is weighing it against one's own circumstances, health priorities, and appetite for the unknown. Claire, the Leeds teacher, eventually enrolled in a digital intervention study that required brief online check-ins and quarterly questionnaires. She describes it as "surprisingly manageable" — a phrase that captures what many volunteers discover once the initial uncertainty fades.
研究の知恵